Cover Image
市場調查報告書

退行性星細胞腫:開發中產品分析

Anaplastic Astrocytoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229766
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
退行性星細胞腫:開發中產品分析 Anaplastic Astrocytoma - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 118 Pages
簡介

退行性星細胞瘤是第三級的腫瘤。佔腦腫瘤整體的2%。是由支援神經細胞的星狀膠細胞發病的神經膠腫瘤的一種。退行性星細胞瘤比第二級的星狀細胞成長更快。腫瘤細胞外觀並不統一,會侵入週邊組織。常見的症狀有頭痛、四肢無力感,動作笨拙、步行困難、痙攣發作等。常發於30∼50歲的男女,有男性較女性為多的傾向。治療方法依腫瘤位置及病情發展不同而異,一般是進行外科手術及放射線療法,中間或之後也可能再併用化療。

本報告提供退行性星細胞腫的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

退行性星細胞腫概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

退行性星細胞腫:企業開發中的治療藥

退行性星細胞腫:大學/機關研究中的治療藥

退行性星細胞腫:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

退行性星細胞腫:企業開發中的產品

退行性星細胞腫:大學/機關研究中的產品

退行性星細胞腫的治療藥開發企業

  • Aduro BioTech, Inc.
  • Axelar AB
  • Boehringer Ingelheim GmbH
  • Burzynski Research Institute, Inc.
  • Cavion LLC
  • Celldex Therapeutics, Inc.
  • e-Therapeutics Plc
  • Medicenna Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Orbus Therapeutics, Inc.
  • Pfizer Inc.
  • Tocagen Inc.
  • TVAX Biomedical, Inc.

退行性星細胞腫:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

退行性星細胞腫:最近的開發平台趨勢

退行性星細胞腫:暫停中的計劃

退行性星細胞腫:開發中止的產品

退行性星細胞腫:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8632IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 7 and 7 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.Anaplastic Astrocytoma.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaplastic Astrocytoma Overview
  • Therapeutics Development
    • Pipeline Products for Anaplastic Astrocytoma - Overview
    • Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis
  • Anaplastic Astrocytoma - Therapeutics under Development by Companies
  • Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes
  • Anaplastic Astrocytoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Anaplastic Astrocytoma - Products under Development by Companies
  • Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes
  • Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
    • AngioChem Inc.
    • Astellas Pharma Inc.
    • Axelar AB
    • Boehringer Ingelheim GmbH
    • Burzynski Research Institute, Inc.
    • Cavion LLC
    • Celldex Therapeutics, Inc.
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Orbus Therapeutics, Inc.
    • Pfizer Inc.
    • Tocagen Inc.
    • TVAX Biomedical, Inc.
  • Anaplastic Astrocytoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antineoplaston Therapy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bendamustine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-1401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Gliomas - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNX-2401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eflornithine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel trevatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVI-Brain-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anaplastic Astrocytoma - Dormant Projects
  • Anaplastic Astrocytoma - Discontinued Products
  • Anaplastic Astrocytoma - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
      • Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1
      • Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anaplastic Astrocytoma, H2 2016
  • Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Anaplastic Astrocytoma - Pipeline by AngioChem Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Axelar AB, H2 2016
  • Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2016
  • Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2016
  • Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2016
  • Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anaplastic Astrocytoma - Dormant Projects, H2 2016
  • Anaplastic Astrocytoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Anaplastic Astrocytoma, H2 2016
  • Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top